This trial is active, not recruiting.

Condition multiple sclerosis
Treatments immuno-ablation and autologous cd34 selected hematopoietic stem cell transplantation (hsct),, standard therapy
Phase phase 2
Sponsor Ottawa Hospital Research Institute
Collaborator Multiple Sclerosis Scientific Research Foundation
Start date August 2001
End date December 2012
Trial size 24 participants
Trial identifier NCT01099930, 200037401H


Multiple sclerosis is an autoimmune disease. We are studying whether high dose chemotherapy and autologous stem cell transplant can replace the autoreactive immune system and if this reduces clinical inflammatory disease in the central nervous system (CNS). A second goal is to examine whether there is long-term stabilization or improvement in disability scores if the inflammatory disease is controlled.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
(Active Comparator)
Patients meeting inclusion/exclusion criteria not consenting to treatment will be requested to consent to control group and followed while receiving standard of care.
standard therapy
Patient will receive standard therapy as decided upon by their treating neurologist.
Patients will undergo stem cell transplantation for the treatment of Multiple Sclerosis
immuno-ablation and autologous cd34 selected hematopoietic stem cell transplantation (hsct),
Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day. Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant

Primary Outcomes

3 year MS activity free survival
time frame: 3 year follow-up post transplant

Secondary Outcomes

Transplant related morbidity
time frame: 3 year follow-up post transplant
Transplant related mortality
time frame: 3 years
Time to MS treatment failure
time frame: 3 years
rate of immune reconstitution following treatment
time frame: 3 years

Eligibility Criteria

Male or female participants from 18 years up to 50 years old.

Inclusion Criteria: - Age between 18 and 50 years - The diagnosis of active multiple sclerosis with relapses or progression and sustained accumulated impairment, made by a neurologist expert in the field - Patient considered at high risk of progression - EDSS Cerebellar Functional score greater than or equal to 3 OR EDSS Pyramidal Functional score greater than or equal to 3 - EDSS between greater than or equal to 3 and less than or equal to 6 - Evidence of current disease activity - Evidence of progression or continued relapses or worsening MRI after at least one year of therapy with interferon-B1, glatiramer acetate, Mitoxantrone, or other conventional dose immunosuppressive drug therapy - If a patient has previously received a cytotoxic agent (Mitoxantrone, Cyclophosphamide etc.) they must have normal bone marrow morphology and cytogenetics before being considered eligible for this study - MRI brain scan that satisfies the MRI criteria of Paty or Fazekas for the diagnosis of multiple sclerosis - No evidence of hepatic inflammation or fibrosis Exclusion Criteria: - Patients with primary progressive multiple sclerosis - Patients with cardiac, renal, pulmonary, hepatic or other organ impairment that would limit their ability to receive dose intensive immunosuppressive therapy including high dose chemotherapy and ASCT - Patient with any active or chronic infection - Patients who are seropositive for HIV1, HIV2, Hepatitis B Surface Antigen, and Hepatitis C - Patients with a previous history of a malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year - Patients whose life expectancy is severely limited by another co-morbid illness - Patients with evidence of myelodysplasia or other non-autoimmune cytopenia - Patients having received a cytotoxic agent within one month of enrolling in this study - Pregnancy or risk of pregnancy. This includes patients that are unwilling to practice active contraception during the time of chemotherapy - Patients with hypersensitivity to rabbit proteins - Patients unable to give written informed consent in accordance with research ethics board guidelines - Patients having previous exposure to natalizumab or alemtuzumab.

Additional Information

Official title Targeting Multiple Sclerosis as an Autoimmune Disease With Intensive Immunoablative Therapy and Immunological Reconstitution: A Potential Curative Therapy for Patients With a Predicted Poor Prognosis
Principal investigator Harold L Atkins, MD
Trial information was received from ClinicalTrials.gov and was last updated in May 2012.
Information provided to ClinicalTrials.gov by Ottawa Hospital Research Institute.